Skip to main content
Fig. 5 | Respiratory Research

Fig. 5

From: Cisplatin treatment induced interleukin 6 and 8 production alters lung adenocarcinoma cell migration in an oncogenic mutation dependent manner

Fig. 5

Scratch assay of KRAS (A549) and EGFR (PC-9) mutant cell lines following cisplatin, erlotinib, IL-6 and IL-8 mono and combination treatment. a Changes in gap area over time (12 h) and treatment of KRAS mutant cell line (A549) using IL-6 (100 ng/ml), IL-8 (100 ng/ml) and cisplatin (30 nM) or erlotinib (100 nM). Magnification is 10x. This is a single experiment representative of n = 3. b Quantification of gap area in KRAS mutant cell line (A549) cultures. Data are presented as % of gap area compared to gap area of untreated A549 cell layers SEM and significant changes are marked as (P < 0.05), (P < 0.001) and (P < 0.0002). c Changes in gap area over time (12 h) and treatment of EGFR mutant cell line (PC-9) using IL-6 (100 ng/ml), IL-8 (100 ng/ml) and cisplatin (30 nM) or erlotinib (100 nM). Magnification is 10x. Representative picture of n = 3. d Quantification of gap area in EGFR mutant cell line (PC-9) cultures. Data are presented as % of gap area compared to gap area of untreated PC-9 cell layers SEM and significant changes are marked as (P < 0.05), (P < 0.001) and (P < 0.0002)

Back to article page